OncoQuest’s second generation products are based on molecular constructs derived from epsilon immunoglobulin (IgE) licensed from UCLA, Stanford University, and Advanced Immune Therapeutics. These antigen specific monoclonal IgE antibodies are currently under preclinical development. Not only do they induce potent cellular immunity but they also sensitize IgE effector cells to directly attack cancer cells and modify the associated solid tumor stroma.
OncoQuest’s technology is supported by an experienced management team, a global network of collaborators, an extensive patent portfolio and considerable scientific, and clinical publications in peer reviewed journals.
OncoQuest’s recent partnership with Shenzhen Hepalink Pharmaceutical Co., Ltd., a China based global pharmaceutical company, provides $ 13,000,000 (U.S.) for the Company to accelerate progress in the development of this scientifically, clinically and commercially important approach to cancer management as combinatorial immunotherapy becomes a primary component of cancer treatment. In addition, OncoQuest has established a Joint Venture with Shenzhen Hepalink to develop immunotherapeutic products for the Greater China market. This joint venture will be managed by Dr. Eric Shi (Professor of Oncology, Nanjing Medical University) and will have a registered capital of $ 9,259,259 (U.S.).